NCT05547906View on ClinicalTrials.gov

Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Solid Tumor
Interventions
DRUG

ASCA101

IV infusion Twice a Week, 8 times per each Cycle

Trial Locations (2)

13620

Seoul national university bundang hospital, Seongnam-si

90027

California Research Institute, Los Angeles

Sponsors

Lead Sponsor

MetaFines
All Listed Sponsors
lead

MetaFines

INDUSTRY

NCT05547906 - Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter